Drug Database
EP

epidermal growth factor receptor (EGFR pharmDx / EGFR pharmDx Kit)

✓ Approved

Dako · EGFR · Companion diagnostic

What is epidermal growth factor receptor?

epidermal growth factor receptor is a companion diagnostic developed by Dako. It is approved for therapeutic indications via others.

Drug Profile

Brand NamesEGFR pharmDx, EGFR pharmDx Kit
CompanyDako
Drug ClassCompanion diagnostic
Molecular TargetEGFR
RouteOthers
StatusApproved
Sources: ClinicalTrials.gov, Dako

Mechanism of Action

Molecular Targets

epidermal growth factor receptor acts on 1 molecular target:

EGFRepidermal growth factor receptor (ERBB1, NNCIS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

epidermal growth factor receptor is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

Related Research Articles

PubMedNature communications2026-08-26

Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2- breast cancer.

Cai Jia-Yang JY, Huang Min-Ying MY, Yang Shao-Ying SY, Zhang Fang-Lin FL et al.

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ /HER2-) breast cancer is the most common subtype in females, frequently challenged by resistance to endocrine therapy and CDK4/6 inhibitors. Here we show that N-acetylneuraminate synthase (NANS) is significantly upregulated in female HR+ /HER2- breast cancer patients, inversely correlating with patient prognosis. Functionally, NANS promotes tumor growth and confers resistance to tamoxifen and CDK4/6 inhibitors independently of its canonical enzymatic activity. Mechanistically, NANS recruits ubiquitin-specific protease 7 (USP7) to deubiquitinate and stabilize large tumor suppressor kinase 2 (LATS2), leading to canonical Hippo pathway activation and upregulation of estrogen receptor α and CDK4. Reintroducing LATS2 into NANS-depleted cells partially rescues the impaired growth-promoting and drug-resistant phenotypes in vitro and in vivo. Furthermore, the clinical relevance of the NANS-USP7/LATS2 axis is confirmed in patient-derived female HR+ /HER2- breast cancer samples. Together, our findings unveil an enzymatic activity-independent role for NANS in driving therapy resistance, nominating it as a promising therapeutic target.

PMID 42642385
Read full article →
PubMedJournal of Cancer2026-08-26

Erratum: Overexpression of Platelet-Derived Growth Factor Receptor Α D842V Mutants Prevents Liver Regeneration and Chemically Induced Hepatocarcinogenesis via Inhibition of MET and EGFR: Erratum.

Du Zhao-Qing ZQ, Dong Jian J, Li Mu-Xing MX, Zhang Jian-Fei JF et al.

[This corrects the article DOI: 10.7150/jca.44492.].

PMID 42643803
Read full article →
PubMedBreastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine2026-08-26

Fentanyl and Sufentanil in Labor Analgesia and Lactational Mastitis Risk: Evidence from a Retrospective Cohort Combined with Network Pharmacology.

Song Qing Q, Li Mengjuan M, Wang Qi Q, Zhao Qing Q et al.

Lactational mastitis (LM) is a common postpartum inflammatory disorder. Fentanyl and sufentanil are widely used for labor analgesia; however, their association with postpartum LM and the underlying molecular mechanisms remain unclear. A single-center retrospective cohort study including 201 women was conducted to evaluate the association between sufentanil-based neuraxial labor analgesia and the occurrence of postpartum LM using logistic regression. In parallel, network pharmacology, protein-protein interaction analysis, Gene Ontology/Kyoto Encyclopedia of Genes and Genomes enrichment, and molecular docking were performed to explore fentanyl- and sufentanil-related molecular targets and potential mechanisms. Women receiving sufentanil-based neuraxial labor analgesia had a higher incidence of LM than women without labor analgesia, and logistic regression showed increased odds of LM in the exposed group (odds ratio = 8.758). Network pharmacology identified 20 shared targets between the drugs and LM, with core nodes including tumor necrosis factor (TNF), IL6, epidermal growth factor receptor (EGFR), ESR1, and NR3C1, which were mainly enriched in inflammation- and stress-related pathways such as NF-κB, mitogen-activated protein kinase (MAPK) and HIF-1. Molecular docking indicated that both opioids could form stable interactions with multiple targets involved in inflammation, endocrine regulation, and cell survival. The clinical findings suggest a potential association between sufentanil-based neuraxial labor analgesia and postpartum LM, while the network pharmacology and molecular docking analyses provide hypothesis-generating evidence for opioid-related inflammatory, immune, endocrine, and tissue-repair pathways. Prospective studies are needed to validate these findings and clarify causality.

PMID 42643000
Read full article →
PubMedIntractable & rare diseases research2026-08-26

Japanese intractable and rare dermatologic diseases: From the official skin-centered nanbyo core to an illustrative mechanism-based framework.

Han Yue Y, Qin Tian-Ge TG, Song Peipei P

Japan's designated intractable disease (nanbyo) framework combines a population threshold with unresolved pathogenesis or treatment, long-term care needs, objective diagnostic criteria, and severity-linked assistance with medical expenses. We conducted a targeted narrative review of official Japanese sources and biomedical literature through August 3, 2026. Evidence ranged from regulatory approvals and randomized trials to observational, case-report, and preclinical data, so therapeutic maturity was assessed separately from mechanistic plausibility. We distinguished the 12 official skin/connective-tissue entries from six purposively selected designated entries or disease groups with decisive cutaneous phenotypes or Japan-specific translational value. The resulting 18-entry framework is illustrative, not exhaustive. It highlights Japan-specific biology or evidence regarding xeroderma pigmentosum, acquired idiopathic generalized anhidrosis, DPP-4 inhibitor-related bullous pemphigoid, generalized pustular psoriasis, cold-medicine-related SJS/TEN, anti-MDA5 dermatomyositis, and Nakajo-Nishimura syndrome. Recently approved indications or uses include dupilumab for adult bullous pemphigoid, IL-36 receptor blockade, topical COL7A1 gene delivery, autologous gene-corrected epidermal sheets, MEK inhibition, IL-1 blockade, and topical mTOR inhibition; JAK-interferon strategies remain investigational. We contend that Japan's designation infrastructure could become an interoperable translational platform linking natural-history cohorts, endotype-defined enrollment, mechanism-aligned endpoints, and multinational adaptive trials.

PMID 42643679
Read full article →
PubMedFrontiers in dental medicine2026-08-26

Effect of glycaemic control on growth factor release and in-vitro biological properties of advanced and injectable platelet-rich fibrin in type 2 diabetes Mellitus.

Kashyap Shanker Rajesh R, Rao Anupama A, Prabhu Ashwini A, Kumar Vijaya V et al.

Platelet-rich fibrin has shown regenerative potential in periodontal treatments; nonetheless, patients with Type 2 diabetes mellitus (T2DM) may experience altered biological activities. Therefore, this study aimed to evaluate the regenerative potential and growth factor release profiles of advanced platelet-rich fibrin (A PRF) and injectable platelet-rich fibrin (i-PRF) derived from participants with controlled and uncontrolled T2DM. This study compared n = 87 (29 per group) participants-controlled T2DM, uncontrolled T2DM, and Healthy non-diabetic groups-analysing blood samples for HbA1c, platelet count, and growth factors like Vascular endothelial growth factor (VEGF), Platelet-derived growth factor-BB (PDGF-BB), Insulin-like growth factor-1 (IGF-1), Transforming growth factor-beta 1 (TGF-β1), Transforming growth factor-beta 2 (TGF-β2) via Enzyme-linked immunosorbent assay (ELISA), assessing cytocompatibility with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, and employing statistical methods like Analysis of variance (ANOVA) correlation, and regression. PRF derived from participants with uncontrolled T2DM demonstrated significantly reduced PDGF-BB and TGF-β2 release compared with healthy participants in both A-PRF (P = 0.016), i-PRF (P = 0.033), and A-PRF (P = 0.002) and i-PRF (P = 0.0034. VEGF release was significantly lower in uncontrolled T2DM than in well-controlled T2DM in both A-PRF (P = 0.0096) and i-PRF (P = 0.0023). Compared with the uncontrolled T2DM group, well-controlled T2DM exhibited significantly higher VEGF release in both A-PRF (P = 0.0096) and i-PRF (P = 0.0023), and significantly higher IGF-1 (P < 0.05) and TGF-β2 (P = 0.033) levels in i-PRF. Platelet counts were comparable across the study groups, whereas cell viability was highest in PRF from healthy participants. HbA1c was not independently associated with the evaluated growth factor concentrations in multivariable analyses. A-PRF and i-PRF derived from participants with well-controlled T2DM exhibited biological properties comparable to those of healthy non-diabetic individuals, whereas uncontrolled T2DM was associated with reduced release of key growth factors, indicating compromised healing potential. These findings suggest that achieving good glycaemic control may optimize the biological performance of PRF for periodontal regenerative therapy. However, the present findings are based on in vitro analyses; confirmation through well-designed prospective clinical studies remains essential before these findings can be translated into routine clinical practice.

PMID 42643293
Read full article →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-08-26

State-Programmable Conductive and Reactivatable Bio-Adhesive for High-Fidelity Epidermal Biointerfaces.

Ahmed Salahuddin S, Momin Marzia M, Ren Jiashu J, Wang Xinyi X et al.

Owing to the inherent trade-off between conformal wetting and mechanical stability at the electrode-skin interface, achieving both microscale conformality and mechanical stability for epidermal electrophysiology remains challenging. Ionically conductive gels provide low interfacial impedance through fluidic wetting but suffer from dehydration and instability, whereas dry soft electrodes offer mechanical stability but lack the rheological adaptability needed for intimate skin contact. Here, we report a state-programmable graft interpenetrating network (g-IPN) that enables a printable and reactivatable conductive adhesive (RCA). The RCA simultaneously achieves high electrical conductivity, state-dependent adhesion, and reversible viscoelasticity. By transitioning from a mechanically robust solid film to a fluidic state via solvent activation, the RCA infiltrates complex skin surfaces and hair-occluded regions, delivering lower interfacial impedance than traditional gels. These properties enable stable electroencephalogram (EEG) and pulse recordings across both rigid and soft electrode platforms, establishing a scalable strategy for high-fidelity epidermal bioelectronic interfaces.

PMID 42643078
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about epidermal growth factor receptor